| ISPC 0.1365 17.17% | CTNT 0.0953 -40.73% | BYND 0.8226 5.19% | YXT 0.496 34.05% | TZA 5.08 -6.45% | EFOI 6.49 210.53% | TSLL 13.9 6.35% | NVDA 201.68 1.68% | BITO 10.63 2.71% | NFLX 97.31 -9.72% | INTC 68.5 0.00% | ZSPC 0.0536 -38.46% | TQQQ 58.59 3.83% | SOXS 18.87 -6.95% | TSLA 400.62 3.01% | XLE 55.02 -2.76% | AMC 1.86 15.53% | SCO 8.47 9.72% | PLUG 2.78 -2.80% | BMNG 1.6 4.58% | IBIT 43.94 2.83% | AAL 12.78 4.16% | BZAI 2.52 45.66% | CRML 12.56 35.49% | SOFI 19.43 2.10% | HIVE 2.51 14.87% | GRAB 4.21 4.73% | SPY 710.14 1.21% | SQQQ 56.39 -3.79% | SOXL 94.68 7.14% | SMR 12.65 10.87% | BMNR 22.95 2.27% | SNAP 6.03 0.17% | UCAR 1.49 29.57% | HIMS 28.82 6.78% | LZMH 0.1736 -84.07% | HYG 80.65 0.37% | DRIP 5.25 9.83% | ONDS 10 -1.96% | DVLT 0.758 -9.49% | AAPL 270.23 2.59% | QQQ 648.85 1.31% | MARA 11.6 0.43% | MSTR 166.52 11.80% | AMZN 250.56 0.34% | PLTR 146.39 2.54% | SPDN 9.13 -1.19% | PBM 7.6 29.47% | IONQ 46.09 3.16% | MSFT 422.79 0.60%

Calumet, Inc. (NASDAQ:CLMT) Sees Positive Analyst Sentiment Amidst Strategic Growth Initiatives

Calumet, Inc. (NASDAQ:CLMT) is a diversified manufacturer and marketer specializing in specialty branded products for consumer and industrial markets. The company operates through its segments: Specialty Products and Solutions, Montana/Renewables, and Performance Brands, offering a wide range of products such as solvents, lubricating oils, renewable fuels, and high-performance consumer products.

The stock consensus target price for Calumet has experienced fluctuations over the past year. Last month, the average price target was $20, reflecting optimism about the company's performance. This is an increase from the $16.63 target three months ago, indicating a positive shift in analyst sentiment. However, a year ago, the target was slightly higher at $20.42, showing some stability in the long-term outlook.

Calumet's recent performance in the renewable energy sector is noteworthy. Montana Renewables, a subsidiary, has achieved industry-leading breakeven costs and positive EBITDA, even in a challenging market. 

Financial performance also plays a crucial role in shaping analyst expectations. Despite reporting a net loss of $147.9 million in Q2 2025, Calumet achieved an adjusted EBITDA of $76.5 million. The company has been proactive in cost reduction, achieving $42 million in operating cost savings year-over-year, which may bolster confidence in its future prospects.

Calumet's strategic initiatives, such as the MaxSAF-150 project and securing a $782 million DOE loan, are expected to drive significant cash flow and margin expansion by 2026. These developments, along with strong performance in the Specialties segment, contribute to the overall positive outlook for the company, as reflected in the recent stock price increase of 12.5%.

Published on: November 7, 2025